Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Anne-Sophie KubaschP PeterlinThomas CluzeauK S GötzeK SockelR TeipelMadlen JentzschH AttalahM SebertF ChermatS GloaguenM PuttrichMichael CrossM SchneiderS KayserD SchippA GiagounidisI Tirado-GonzalezA DescotArjan A van de LoosdrechtA WeigertKlaus H MetzelerP FenauxH MedyoufUwe PlatzbeckerLionel AdesPublished in: Leukemia (2023)